Cancer immunotherapy .net
Information on human tumours
pilot studies 3
cancerimmunotherapy@yahoo.com
tumour type
Colorectal carcinoma
Results in brief:

4 patients with a life expectancy of less than 3 - 6 months treated.
2 showed marked general improvement and lived for 10 and 28 months, respectively.

Research in progress
2005
Krastev et al. (2005)
tumour type
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitive to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

Experts
I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors
Information for patients
I want to support this research or  more information on the EPTI fund supporting this research
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands
1